Combination of anti-PD-L1 and radiotherapy in hepatocellular carcinoma: a mathematical model with uncertain parameters

被引:1
|
作者
Shafiekhani, Sajad [1 ]
Gheibi, Nematollah [2 ,3 ]
Esfahani, Azam Janati [2 ,3 ,4 ]
机构
[1] Smart Univ Med Sci, Artificial Intelligence Dept, Tehran, Iran
[2] Qazvin Univ Med Sci, Res Inst Prevent Noncommunicable Dis, Cellular & Mol Res Ctr, Qazvin, Iran
[3] Qazvin Univ Med Sci, Sch Paramed Sci, Dept Med Biotechnol, Qazvin, Iran
[4] Qazvin Univ Med Sci, Dept Med Biotechnol, Shahid Bahonar Blvd, Qazvin 3419915315, Iran
关键词
Hepatocellular carcinoma; anti-PD-L1; radiotherapy; in silico; ordinary differential equations; fuzzy theorem; CHECKPOINT BLOCKADE; RADIATION; IMMUNOTHERAPY; MECHANISMS;
D O I
10.1177/00375497221133846
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Blockade of programmed death-ligand-1 (PD-L1) as a new method of immunotherapy for cancers has shown limited efficacy in hepatocellular carcinoma (HCC). The combination of anti-PD-L1 and radiotherapy (RT) enhances the antitumor effect in HCC cancer. The efficacy and interactions of these treatments can be addressed by a mathematical model. We developed a mathematical model using a set of ordinary differential equations (ODEs). The variables include cancer cells, cytotoxic T lymphocytes (CTLs), programmed cell death-1 (PD-1), PD-L1, anti-PD-L1, and ionizing radiation. The model is parameterized with imprecise data set of murine HCC model and the effect of parametric uncertainty is assessed by the fuzzy theorem. The global sensitivity analysis (GSA) is performed to assess model robustness against perturbation in parameters and to identify the most influential parameters on the dynamics of cells and proteins. In silico predictions are consistent with experimental data. The model simulation shows that anti-PD-L1 and RT have a synergistic effect. In silico assessment of treatments' efficacy in the fuzzy setting of parameters revealed that anti-PD-L1 therapy, RT, and combination treatment caused the uncertainty band of tumor cells to lead to lower populations. This model as a validated rigorous simulation framework can be used to deepen our understanding of tumor and immune cell interactions and helps clinicians to investigate the efficacy of different time schedules of anti-PD-L1, RT, and combination therapy. The fuzzy theorem in conjunction with the classical ODE model that is parameterized by imprecise data was used to predict reliable outcomes of treatment.
引用
收藏
页码:313 / 325
页数:13
相关论文
共 50 条
  • [21] Anti-PD-L1 immunotherapy inhibits the progression of sorafenib acquired resistant hepatocellular carcinoma by inducing immune activation
    Xu, D.
    Zhu, Y.
    Yang, J.
    Zhang, Z.
    Li, T.
    Yang, J.
    Dong, Q.
    Qin, L.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1748 - 1749
  • [22] Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma
    Bonan Zhao
    Zhipeng Dong
    Weixing Liu
    Fangning Lou
    Qiyan Wang
    Hao Hong
    Yue Wang
    Journal of Nanobiotechnology, 19
  • [23] Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma
    Zhao, Bonan
    Dong, Zhipeng
    Liu, Weixing
    Lou, Fangning
    Wang, Qiyan
    Hong, Hao
    Wang, Yue
    JOURNAL OF NANOBIOTECHNOLOGY, 2021, 19 (01)
  • [24] Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
    Philips, George K.
    Atkins, Michael
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 39 - 46
  • [25] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [26] New Fractional Cancer Mathematical Model via IL-10 Cytokine and Anti-PD-L1 Inhibitor
    Ucar, Esmehan
    Ozdemir, Necati
    FRACTAL AND FRACTIONAL, 2023, 7 (02)
  • [27] Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma
    Hirayama, Yukiyoshi
    Gi, Min
    Yamano, Shotaro
    Tachibana, Hirokazu
    Okuno, Takahiro
    Tamada, Satoshi
    Nakatani, Tatsuya
    Wanibuchi, Hideki
    CANCER SCIENCE, 2016, 107 (12): : 1736 - 1744
  • [28] Combination of ANTI-PD-1/ANTI-PD-L1 Antibodies With the Distinct Character Exerts Preferable Anti-Tumor Immune Cycle in a Murine Neuroblastoma Model
    Inoue, S.
    Horiuchi, Y.
    Setoyama, Y.
    Takeuchi, Y.
    Murakami, T.
    Odaka, A.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S157 - S157
  • [29] Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
    Philippou, Yiannis
    Sjoberg, Hanna T.
    Murphy, Emma
    Alyacoubi, Said
    Jones, Keaton I.
    Gordon-Weeks, Alex N.
    Phyu, Su
    Parkes, Eileen E.
    Gillies McKenna, W.
    Lamb, Alastair D.
    Gileadi, Uzi
    Cerundolo, Vincenzo
    Scheiblin, David A.
    Lockett, Stephen J.
    Wink, David A.
    Mills, Ian G.
    Hamdy, Freddie C.
    Muschel, Ruth J.
    Bryant, Richard J.
    BRITISH JOURNAL OF CANCER, 2020, 123 (07) : 1089 - 1100
  • [30] Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
    Yiannis Philippou
    Hanna T. Sjoberg
    Emma Murphy
    Said Alyacoubi
    Keaton I. Jones
    Alex N. Gordon-Weeks
    Su Phyu
    Eileen E. Parkes
    W. Gillies McKenna
    Alastair D. Lamb
    Uzi Gileadi
    Vincenzo Cerundolo
    David A. Scheiblin
    Stephen J. Lockett
    David A. Wink
    Ian G. Mills
    Freddie C. Hamdy
    Ruth J. Muschel
    Richard J. Bryant
    British Journal of Cancer, 2020, 123 : 1089 - 1100